Warning! GuruFocus detected
6 Severe warning signs
with 6OP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
OSE Immunotherapeutics SA
ISIN : FR0012127173
Compare
Compare
Traded in other countries / regions
OSE.France0RAD.UK6OP.Germany IPO Date
2015-04-07Description
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.39 | |||||
| Equity-to-Asset | 0.58 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 12.91 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 0.37 | |||||
| Beneish M-Score | 7.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44.6 | |||||
| 3-Year EBITDA Growth Rate | 8.6 | |||||
| 3-Year EPS without NRI Growth Rate | -6.2 | |||||
| 3-Year FCF Growth Rate | 7 | |||||
| 3-Year Book Growth Rate | -32.2 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 143.47 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.33 | |||||
| 9-Day RSI | 47.82 | |||||
| 14-Day RSI | 46.9 | |||||
| 3-1 Month Momentum % | -12.82 | |||||
| 6-1 Month Momentum % | 1.29 | |||||
| 12-1 Month Momentum % | 48.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.93 | |||||
| Quick Ratio | 4.93 | |||||
| Cash Ratio | 1.49 | |||||
| Days Sales Outstanding | 10.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | 5.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 77 | |||||
| Net Margin % | 65.84 | |||||
| FCF Margin % | 83.44 | |||||
| ROE % | 108.78 | |||||
| ROA % | 45.52 | |||||
| ROIC % | 66.96 | |||||
| 3-Year ROIIC % | -4609.43 | |||||
| ROC (Joel Greenblatt) % | 291.11 | |||||
| ROCE % | 64.68 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 3.67 | |||||
| Forward PE Ratio | 8.72 | |||||
| PE Ratio without NRI | 3.59 | |||||
| PS Ratio | 2.28 | |||||
| PB Ratio | 1.7 | |||||
| Price-to-Tangible-Book | 3.82 | |||||
| Price-to-Free-Cash-Flow | 2.83 | |||||
| Price-to-Operating-Cash-Flow | 2.83 | |||||
| EV-to-EBIT | 2 | |||||
| EV-to-Forward-EBIT | -5.92 | |||||
| EV-to-EBITDA | 1.94 | |||||
| EV-to-Forward-EBITDA | 2.01 | |||||
| EV-to-Revenue | 1.53 | |||||
| EV-to-Forward-Revenue | 1.24 | |||||
| EV-to-FCF | 1.84 | |||||
| Price-to-GF-Value | 15.26 | |||||
| Price-to-Graham-Number | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 5.25 | |||||
| Earnings Yield (Greenblatt) % | 50 | |||||
| FCF Yield % | 41.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OSE Immunotherapeutics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 69.915 | ||
| EPS (TTM) (€) | 1.73 | ||
| Beta | 1.36 | ||
| 3-Year Sharpe Ratio | 0.27 | ||
| 3-Year Sortino Ratio | 0.5 | ||
| Volatility % | 80.23 | ||
| 14-Day RSI | 46.9 | ||
| 14-Day ATR (€) | 0.214565 | ||
| 20-Day SMA (€) | 6.6595 | ||
| 12-1 Month Momentum % | 48.53 | ||
| 52-Week Range (€) | 4.435 - 10.68 | ||
| Shares Outstanding (Mil) | 21.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OSE Immunotherapeutics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OSE Immunotherapeutics SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
OSE Immunotherapeutics SA Frequently Asked Questions
What is OSE Immunotherapeutics SA(FRA:6OP)'s stock price today?
The current price of FRA:6OP is €6.41. The 52 week high of FRA:6OP is €10.68 and 52 week low is €4.43.
When is next earnings date of OSE Immunotherapeutics SA(FRA:6OP)?
The next earnings date of OSE Immunotherapeutics SA(FRA:6OP) is .
Does OSE Immunotherapeutics SA(FRA:6OP) pay dividends? If so, how much?
OSE Immunotherapeutics SA(FRA:6OP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers